Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Takeda Pharmaceutical Co's Other Current Receivables for the quarter that ended in Mar. 2026 was 円-101,007 Mil.
Takeda Pharmaceutical Co's quarterly Other Current Receivables
increased
from Sep. 2025 (円13,275.00 Mil) to Dec. 2025 (円21,457.00 Mil) but then
stayed the same
from Dec. 2025 (円21,457.00 Mil) to Mar. 2026 (円-101,007.00 Mil).
Takeda Pharmaceutical Co's annual Other Current Receivables
declined
from Mar. 2024 (円-21,065.00 Mil) to Mar. 2025 (円-45,642.00 Mil) and
declined
from Mar. 2025 (円-45,642.00 Mil) to Mar. 2026 (円-101,007.00 Mil).
Takeda Pharmaceutical Co Other Current Receivables Related Terms
Takeda Pharmaceutical Co Other Current Receivables Historical Data
* Premium members only.
The historical data trend for Takeda Pharmaceutical Co's Other Current Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co Other Current Receivables Chart
What does a Other Current Receivables of 円-101,007 Mil mean?
Takeda Pharmaceutical Co (TSE:4502) has a Other Current Receivables of 円-101,007 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Other Current Receivables too high?
Takeda Pharmaceutical Co's current Other Current Receivables is 円-101,007 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Other Current Receivables compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Other Current Receivables of 円-101,007 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Other Current Receivables is 円-101,007 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TSE:4502) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,542.68, compared to a current price of 円5,555.00 — trading 22.3% above its estimated fair value. The current Other Current Receivables is 円-101,007 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TSE:4502), the current Other Current Receivables is 円-101,007 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TSE:4502) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円5,555.00 is trading 22.3% above its estimated GF Value™ of 円4,542.68.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TSE:4502:
Other Current Receivables: 円-101,007 Mil
GF Value™: 円4,542.68 vs. price of 円5,555.00 (22.3% above fair value)
No single metric tells the full story. See the TSE:4502 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
65GF Score
Get the complete analysis for TSE:4502
Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4502 has been successfully added to your 
